

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

**Claim 1. (currently amended)** A therapeutic agent composition for treating glaucoma comprising a combination of pharmaceutically effective amounts of drugs consisting essentially of (i) a Rho kinase inhibitor or a salt or an ester thereof and (ii) a prostaglandin or a salt or ester thereof, and optionally a pharmaceutically acceptable carrier.

**Claim 2. (currently amended)** A therapeutic agent composition for treating glaucoma which comprises a combination of pharmaceutically effective amounts of drugs consisting essentially of (i) a Rho kinase inhibitor or a salt or an ester thereof and a (ii) prostaglandin or a salt or an ester thereof, wherein the actions of the Rho kinase inhibitor and the prostaglandin are complemented and/or

enhanced by each other, and optionally a pharmaceutically acceptable carrier.

**Claim 3. (currently amended)** The therapeutic agent composition for treating glaucoma as claimed in claim 1, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexane carboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine, or a salt or an ester thereof.

**Claim 4. (currently amended)** The therapeutic agent composition for treating glaucoma as claimed in claim 1, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost, or a salt or an ester thereof.

Claim 5. (withdrawn - currently amended) A method of treating glaucoma comprising administering to a patient pharmaceutically effective amounts of (i) a Rho kinase inhibitor or a salt or an ester thereof in a combination with (ii) a prostaglandin to a patient, or a salt or an ester thereof.

Claim 6. (withdrawn - currently amended) A method of treating glaucoma comprising administering to a patient pharmaceutically effective amounts of (i) a Rho kinase inhibitor or a salt or an ester thereof in a combination with (ii) a prostaglandin to a patient or a salt or an ester thereof, wherein the actions of the Rho kinase inhibitor or a salt or an ester thereof and the prostaglandin or a salt or an ester thereof are complemented and/or enhanced by each other.

Claim 7. (withdrawn - currently amended) The method of treating glaucoma as claimed in claim 5, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexanecarboxamide, (R)-(+)-N-(1H-

pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine, or a salt or an ester thereof.

**Claim 8. (withdrawn - currently amended)** The method of treating glaucoma as claimed in claim 5, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost, or a salt or an ester thereof.

**Claim 9. (cancelled)**

**Claim 10. (cancelled)**

**Claim 11. (cancelled)**

**Claim 12. (cancelled)**

**Claim 13. (currently amended)** The therapeutic agent composition for treating glaucoma as claimed in claim 2, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexanecarboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-

(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine, or a salt or an ester thereof.

**Claim 14. (currently amended)** The therapeutic agent composition for treating glaucoma as claimed in claim 2, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost, or a salt or an ester thereof.

**Claim 15. (currently amended)** The therapeutic agent composition for treating glaucoma as claimed in claim 3, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost, or a salt or an ester thereof.

**Claim 16. (currently amended)** The therapeutic agent composition for treating glaucoma as claimed in claim 13, wherein the prostaglandin is isopropyl unoprostone,

latanoprost, travoprost or bimatoprost, or a salt or an ester thereof.

**Claim 17. (withdrawn - currently amended)** The method of treating glaucoma as claimed in claim 6, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl) cyclohexanecarboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine, or a salt or an ester thereof.

**Claim 18. (withdrawn - currently amended)** The method of treating glaucoma as claimed in claim 6, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost, or a salt or an ester thereof.

**Claim 19. (withdrawn - currently amended)** The method of treating glaucoma as claimed in claim 7, wherein the

prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost, or a salt or an ester thereof.

**Claim 20. (withdrawn - currently amended)** The method of treating glaucoma as claimed in claim 17, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost, or a salt or an ester thereof.

**Claim 21. (new)** The therapeutic composition for treating glaucoma as claimed in claim 1, wherein the combination of drugs is selected from the group consisting of

- (i) (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide dihydrochloride and isopropyl unoprostone;
- (ii) (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide dihydrochloride and latanoprost;
- (iii) 1-(5-isoquinolinesulfonyl)-homopiperazine dihydrochloride and isopropyl unoprostone; and
- (iv) 1-(5-isoquinolinesulfonyl)-homopiperazine dihydrochloride and latanoprost.

**Claim 22. (new)** The method of treating glaucoma as claimed in claim 5, wherein the combination is selected from the group consisting of

- (i) (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide dihydrochloride and isopropyl unoprostone;
- (ii) (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide dihydrochloride and latanoprost;
- (iii) 1-(5-isoquinolinesulfonyl)-homopiperazine dihydrochloride and isopropyl unoprostone; and
- (iv) 1-(5-isoquinolinesulfonyl)-homopiperazine dihydrochloride and latanoprost.